Marijuana stocks have suffered a terrible beating in the past year or so. Here's a look at six former high-flyers and their prospects for a recovery.
Pfizer is among the current frontrunners for a COVID-19 vaccine, so why is its stock down 13% year to date? And why does one independent research firm say this stock could run much higher?
After Corvus Pharmaceuticals announced that it would initiate an early-stage immunotherapy study in patients with COVID-19, Wedush sees this stock running much higher.
Novavax and Regeneron Pharmaceuticals each made solid progress on Tuesday after each company received a sizable capital injection from the U.S. government’s Operation Warp Speed program.
24/7 Wall Street has picked out a few of the best and brightest coronavirus stocks that could still see a big push as 2020 continues.
Here is a look of a few of the biggest clinical trial and FDA updates to watch for in July 2020.
Pfizer and BioNTech have been collaborating to produce a messenger RNA based vaccine for the past few months, and this work is yielding promising results.
OptiNose shares popped on Tuesday after the company announced that it is making a move toward fighting COVID-19 with its tech.
Intercept Pharmaceuticals stock was crushed early on Monday after the firm received an update from the FDA in regards to its treatment of fibrosis due to nonalcoholoic steatohepatitis.
Royalty Pharma shares entered the market with a bang on Tuesday.
Is it time to buy Amarin? The biopharmaceutical company just announced a new study showing its drug Vascepa can significantly reduce cardiovascular risk in people with diabetes.
Sanofi's announcement that it would be investing in a COVID-19 vaccine production site in France gave shares a boost early Tuesday.
Canaccord Genuity recently released a report detailing some of the biggest biotech catalysts coming out over these next six months.
Johnson & Johnson has announced that it will accelerate initiation of its early stage first-in-human clinical trial for the treatment of COVID-19. Shares got a mild boost on Wednesday from the news.
Amarin is on hold as generic rivals seek to copy its potential blockbuster Vascepa.